Almac Discovery
Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. It is led by an experienced team (ex Pharma and Biotech), with a track record in delivering successful clinical stage programmes. Almac Discovery utilises its capabilities and expertise to discover and develop novel first-in-class/best-in-class NCEs and Novel Protein Therapeutics through to IND-ready stage, after which it seeks to collaborate with partners to continue into clinical development.
Its core expertise and arising portfolio are focussed on two areas:
a) Targeting the Deubiquitinating enzyme class (DUBs) linked to protein homeostasis and degradation through the application of its proprietary Ubi-Plex technology platform, and,
b) Next Generation Protein:Drug Conjugate (PDC) technology platform utilising minimal antigen-binding domains combined with Almac's novel, proprietary linker and payload technology.
Drug programmes derived from these platforms are currently being prosecuted both in house and with external collaborators.
Dr Alan Lamont
VP Business Development and Licensing
Almac Group
Almac Pharma Services are the Drug Product Experts within the Almac Group, offering formulation development & GMP Manufacturing services for small molecule, solid oral dose products for both clinical and commercial supply, as well as commercial packaging of all types of dosage forms, for worldwide release and distribution.
Rory Davidson
Business Development Manager – EU
Manuel Figueiredo
Business Development Manager
Barrington James
Barrington James are a global staffing and resourcing organisation who specialise in placing niche consultants of all levels in the Biotech and Pharmaceutical industry. We offer both short and long term solutions and can provide ad-hoc consultancy support as required. Our offices in Europe, USA and APAC means that we can provide a truly global solution and experience in a market you may not know.
All of our team are dedicated market specialists with unrivalled candidate networks and will be on hand in Hamburg to discuss any assistance you may need to aid you getting your product to market. We have proven experience in knowing the difference between working for a big pharma and a new start-up Biotech and will ensure that the people you hire truly understand your business and what you need to succeed.
Olivia Vigar
Clinical Consultant
Patrick Wagg
European Sales Manager
Roope Ghosh
FSP
Ryan Somerville
Associate Director
Vincenzo Dessena
Clinical Consultant
James Lewis
Executive Director
BioIndustry Association (BIA)
• Pharmaceutical and technological companies
• Universities, research centres, tech transfer offices, incubators and accelerators
• A wide range of life science service providers: investors, lawyers, IP consultants and IR agencies Explore opportunities to influence, connect and save with the BIA.
Alina O'Keeffe
Head of Marketing and Membership Communications
Mr George Caterer
Membership and Business Development Manager at BioIndustry Association
BioPartner UK
We facilitate international partnering for trade, investment and collaborations for UK based Life Sciences organisations. As a membership organisation, we support our members and other UK SMEs and startups, and we signpost global interest to UK expertise.
#internationaltrade #discounts #events #partnering #unitedkingdom
Wiki Molodziejko
Della Chaffe
Dr Alasdair Stamps
Bit Bio
This is possible with our precision cellular reprogramming technology, opti-ox™ - a core component of our Cell Identity Coding Platform. opti-ox is a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through rapid reprogramming of stem cells. ioCells™
Under our ioCells brand we have a wide range of wild type and disease model cells available for research and drug discovery including human iPSC-derived nerve, immune and muscle cells. Our portfolio is expanding at pace and all our cells are powered by opti-ox so are consistent, easy to use and highly defined. Cell therapy
We are currently building a clinical pipeline of cell therapies. Our areas of development are liver, immune and metabolic.
Kam Dhaliwal
Senior VP Business Development & Alliance Management
C4X Discovery
Mrs Bhavna Hunjan
Chief Business Officer
Dr Nick Ray
Chief Scientific Officer
Douglas Vair-Turnbull
Senior Business Development & Strategy Manager
Camena Bioscience
Camena Bioscience's mission is to become the leading provider of synthetic DNA, by using our technology to unlock access to genes with unparalleled accuracy.
We serve a range of pharmaceutical and synthetic biology companies to meet their gene synthesis needs.
Camena Bioscience provides a service for producing long and complex gene sequences, produced in our Cambridge UK labs. We also work strategically with partners to create custom solutions for their needs.
Steve Harvey
CEO
Cancer Research Horizons
Eleanor Stead
Business Development Manager
Kayvan Richter
Marketing Manager
Dr Sophie Piper
Business Development Manager
Thomas Edwards
Business Development Manager
